References:
† Data on File. Abbott Diabetes Care.
‡ The FreeStyle LibreLink app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app.
∆ Terms and conditions apply. Check your eligibility here.
Abbreviations: HbA1c/A1 : glycated haemoglobin; BGM: blood glucose monitoring; CGM: continuous glucose monitoring; HCP: health care professional; hypo: hypoglycemic event; ISF: interstitial fluid; MDI: multiple daily injections; RCT: randomised controlled trial; SMBG: self-monitoring of blood glucose; TIR: time in range; T1D: type 1 diabetes; T2D: type 2 diabetes.
± Work with your healthcare professional to understand your glucose history.
* Scanning the sensor to obtain glucose values does not require lancets. To get a 24-hour glycemic picture, users need to scan at least once every 8 hours
** Sensor is water resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes.
~ Data based on the number of users worldwide for the FreeStyle Libre system compared to the number of users for other leading personal use sensor based glucose monitoring systems.
§ Sensor dimensions: 35mm x 5mm Weight: 5 grams.
# The FreeStyle Libre reader can capture data from within 1cm to 4cm of the sensor, even through clothing.
ф Most people did not feel any discomfort under the skin while wearing the FreeStyle Libre sensor. In a study conducted by Abbott Diabetes Care, 93.4% of patients surveyed (n=30) strongly agree or agree that while wearing the sensor, they did not feel any discomfort under their skin. [29 persons have finished the study; 1 person terminated the study after 3 days due to skin irritations in the area where the sensor touched the skin].
†† Finger pricks are required if glucose readings and alarms do not match symptoms or expectations.
- Ajjan R, et al. Continuous Glucose Monitoring: A Brief Review for Primary Care Practitioners. Adv Ther 2019;36:579-596. https://doi.org/10.1007/s12325-019-0870-x.
- Alva S, et al. Accuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System With Advanced Algorithm in Pediatric and Adult Population With Diabetes. J Diabetes Sci Technol 2020. https://doi.org/10.1177/1932296820958754.
- American Diabetes Association. Standards of medical care in diabetes—2020. Diabetes Care. 2020;43(1):S77-S88.
- Battelino T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019. https://doi.org/10.2337/dci19-0028.
- Beck RW, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care 2019;42(3):400–405. https://doi.org/10.2337/dc18-1444.
- Bolinder J, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388(10057):2254-2263.
- Brixner D, et al. Clinical and Economic Outcomes of Patients with Type 2 Diabetes on Multiple Daily Injections of Basal-bolus Insulin (MDI) Therapy: A Retrospective Cohort Study. Clinical Therapeutics 2019;41(2):303-313. doi: 10.1016/j.clinthera.2018.12.014.
- Carlson AL, et al. Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis. BMJ Open Diab Res Care. 2022. https://doi.org/10.1136/bmjdrc-2021-002590.
- Cengiz E, and Tamborlane WV. A tale of two compartments: interstitial versus blood glucose monitoring. Diabetes Technol Ther. 2009;11 Suppl 1(Suppl 1):S11-S16. doi:10.1089/dia.2009.0002.
- Charleer S, et al. Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study. Diabetes Care 2020;43(2):389-397. https://doi.org/10.2337/dc19-1610.
- Evans M, et al. The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: A Meta-analysis of Clinical Trials and Real-World Observational Studies. Diabetes Ther 2020;11:83-95. https://doi.org/10.1007/s13300-019-00720-0.
- Evans M, et al. Reductions in HbA1c with Flash Glucose Monitoring Are Sustained for up to 24 Months: A Meta-Analysis of 75 Real-World Observational Studies. Diabetes Ther 2022. https://doi.org/10.1007/s13300-022-01253-9.
- Fokkert M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diabetes Research and Care 2019;7:e000809. doi: 10.1136/bmjdrc-2019-000809.
- Foster NC, et al. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018. Diabetes Technol Ther 2019;21(2):66-72. https://doi.org/10.1089/dia.2018.0384.
- FreeStyle Libre 2 User Manual (EU).
- Garden GL, et al. HbA1c and hypoglycaemia outcomes for people with type 1 diabetes due to the introduction of a single-day structured education programme and flash glucose monitoring. Br J Diabetes 2021;21:84-88. https://doi.org/10.15277/bjd.2021.284.
- Haak T, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes. Diabetes Ther. 2016. doi: 10.1007/s13300-016-0223- 6.
- Hirst JA, et al. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care. 2012 Feb;35(2):446-54. doi: 10.2337/dc11-1465.
- Lang J, et al. Expanded Real-World Use Reaffirms Strong Correlation between Scanning Frequency of Flash Glucose Monitoring and Glucose Control. Diabetes 1 June 2019; 68 (Supplement_1): 972–P. https://doi.org/10.2337/db19-972-P.
- Lee WC, et al. Frequency of blood glucose testing among insulin-treated diabetes mellitus patients in the United Kingdom. J Med Econ. 2014 Mar;17(3):167-75. doi: 10.3111/13696998.2013.873722.
- Miller E, Brandner L, Wright E. HbA1c reduction after initiation of the FreeStyle Libre system in type 2 diabetes patients on long-acting insulin or non-insulin therapy [84-LB]. Poster presented at: American Diabetes (ADA) 80th Scientific Sessions.
- Seibold AJ, Minimizing Adverse Skin Reactions to Wearable Continuous Glucose Monitoring Sensors in Patients With Diabetes. J Diabetes Sci Technol. 2021 May;15(3):713-714. doi: 10.1177/1932296820984763.
- Unger J, et al. Practical guidance for using the FreeStyle Libre flash continuous glucose monitoring in primary care. Postgrad Med. 2020 May;132(4):305-313. doi: 10.1080/00325481.2020.1744393.
- Vigersky RA, et al. The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes. Diabetes Technol Ther. 2019 Feb;21(2):81-85. doi: 10.1089/dia.2018.0310.
- Vincze G, et al. Factors Associated With Adherence to Self-Monitoring of Blood Glucose Among Persons With Diabetes. Diabetes Educ 2004;30(1):112-125. doi:10.1177/014572170403000119.
- Wagner J, et al. Invasiveness as a barrier to self-monitoring of blood glucose in diabetes. Diabetes Technol Ther. 2005 Aug;7(4):612-9. doi: 10.1089/dia.2005.7.612.
- Wright E, et al. Diabetes Spectrum. Use of Flash Continuous Glucose Monitoring Is Associated With A1C Reduction in People With Type 2 Diabetes Treated With Basal Insulin or Noninsulin Therapy. 2021;34(2):184–189. https://doi.org/10.2337/ds20-0069.
- Yaron M, et al. Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes. Diabetes Care. 2019 Jul;42(7):1178-1184. doi: 10.2337/dc18-0166.
